Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia

Technology appraisal guidance
Reference number: TA694
Published: 28 April 2021

History

Expected publication

Equality Impact Assessment (Guidance development) (PDF 162 KB)

Published:

28 April 2021

Final draft guidance

Final draft guidance
Public committee slides (PDF 646 KB)

Published:

18 March 2021
Final appraisal document (PDF 294 KB)

Published:

18 March 2021
Committee papers (PDF 1.68 MB)

Published:

18 March 2021

Draft guidance

Draft guidance
Committee papers (PDF 8.81 MB)

Published:

11 December 2020
Public committee slides (PDF 1.14 MB)

Published:

11 December 2020
Public committee slides (PDF 891 KB)

Published:

11 December 2020
Appraisal consultation document (online commenting)
Appraisal consultation document (PDF version) (PDF 322 KB)

Published:

11 December 2020

Invitation to participate

Final scope (PDF 179 KB)

Published:

26 September 2019
Final stakeholder list (PDF 184 KB)

Published:

26 September 2019
Equality impact assessment (Scoping) (PDF 128 KB)

Published:

26 September 2019
NICE's response to comments on the draft scope and provisional stakeholder list (PDF 251 KB)

Published:

26 September 2019